67 / 92
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 4, July/August 2016
AFRICA
269
32. Spence JD. Carotid plaque measurement is superior to IMT: Invited
editorial comment on: Carotid plaque, compared with carotid intima–
media thickness, more accurately predicts coronary artery disease events:
A meta-analysis. Inaba Y, Chen JA, Bergmann SR.
Atherosclerosis
2012;
220
: 34–35.
33. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting C, Lakatta EG,
et al.
Central or peripheral systolic or pulse pressure: which best relates
to target organs and future mortality?
J Hypertens
2009;
27
: 461–467.
34. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker
A,
et al
. Spectrum of heart disease and risk factors in a black urban
population in South Africa (The Heart of Soweto study): a cohort study.
Lancet
2008;
371
: 915–922.
35. Fowkes FGR, ThorogoodM, Connor MP, Lewando-Hundt G, Tzoulaki
I, Tollman SM. Distribution of a subclinical marker of cardiovascular
risk, the ankle brachial index, in a rural African population: SASPI
study.
Eur J Cardiovasc Prev Rehabil
2006;
13
: 964–969.
36. Vorster HH. The emergence of cardiovascular disease during urbanisa-
tion of Africans.
Public Health Nutr
2002;
5
: 239–243.
37. Sun P, Dwyer KM, Merz CNB, Sun W, Johnson CA, Shircore AM,
et
al
. Blood pressure, LDL cholesterol, and intima–media thickness: A test
of the “Response to injury” hypothesis of atherosclerosis.
Arterioscler
Thromb Vasc Biol
2000;
20
: 2005–2010.
38. Yang C, Sun Z, Li Y, Ai J, Sun Q, Tian Y. The correlation between serum
lipid profile with carotid intima–media thickenss and plaque.
BMC
Cardiocasc Discord
2014;
14
: 181.
39. McEniery CM, Wilkinson IB. Large artery stiffness and inflammation.
J Hum Hypertens
2005;
19
: 507–509.
40. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M,
et al
.
Effects of severe hypertension on endothelial and platelet microparticles.
Hypertension
2003;
41
: 211–217.
41. Caviezel S, Dratva J, Schaffner E, Schindler C, Zemp Stutz E, de
Groot E,
et al.
Sex-specific associations of cardiovascular risk factors
with carotid stiffness – Results from the SAPALDIA Cohort Study.
Atherosclerosis
2014;
235
: 576–584.
Confidence Through Clinical
and Real World Experience
1-3
Millions of Patients Treated Across Multiple Indications
4
#1 NOAC prescribed by Cardiologists
*
References:
1.
Patel M.R., Mahaffey K.W., Garg J.
et al.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
N Engl J Med
. 2011;365(10):883–91.
2.
Tamayo S., Peacock W.F., Patel M.R.,
et al.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8.
3.
Camm A.J., Amarenco P., Haas S.
et al.
XANTUS: A Real-World,
Prospective, Observational Study.
4.
Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.
For fullprescribing information,refer to thepackage insertapprovedby theMedicinesRegulatoryAuthority (MCC). S4 XARELTO
®
10 (Film-coated tablets)
.Reg.No.:42/8.2/1046.Eachfilm-coated tabletcontainsrivaroxaban10mg.
PHARMACOLOGICALCLASSIFICATION:
A.8.2Anticoagulants.
INDICATION:
Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO
®
15 and XARELTO
®
20 (Film-coated tablets). Reg. No.: XARELTO
®
15: 46/8.2/0111; XARELTO
®
20: 46/8.2/0112. Each film
coated tablet contains rivaroxaban 15 mg (XARELTO
®
15) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2)
Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).
HCR:
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM.01.2016.1265
*Impact RX Data Oct - Dec 2015
NOAC: Non Vitamin K Oral Anticoagulant